483
Elizabeth I. Buchbinder, M.D.Elizabeth I. Buchbinder, M.D. – FDA 483, Oct 3, 2022
Record Details
An FDA inspection of Dana Farber Cancer Institute in Boston, MA, revealed that a clinical investigation was not conducted in accordance with its investigational plan. Specifically, the firm failed to obtain required brain MRIs and CT scans for multiple subjects within the specified timeframes, with many scans being either missing or significantly delayed. This indicates a serious deviation from the study protocol.
View Company Profile
ID · c83a3a23-0462-4f50-8faf-96f5ba87bb5f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.